## CORRECTION

# BMC Cancer





# Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

Weiwei Huang<sup>1,2,3†</sup>, Chenxi Wang<sup>4†</sup>, Yangkun Shen<sup>4</sup>, Qi Chen<sup>4</sup>, Zhijian Huang<sup>5</sup>, Jian Liu<sup>2</sup>, Xiaoyan Lin<sup>1,3\*</sup>, Lili Wang<sup>2</sup>, Fan Wu<sup>2</sup>, Xinhua Chen<sup>2</sup>, Nani Li<sup>2</sup>, Yi Hong<sup>2</sup>, Mulan Chen<sup>2</sup>, Jieyu Li<sup>6</sup> and Chuanzhong Huang<sup>6</sup>

### Correction: BMC Cancer 24, 39 (2024)

https://doi.org/10.1186/s12885-023-11790-6

Following publication of the original article [1], a typesetting error was noticed in the equal contributions statement. The equal contributions should read as follows: † Weiwei Huang and Chenxi Wang contributed equally to this work.

<sup>†</sup>Weiwei Huang and Chenxi Wang contributed equally to this work.

The online version of the original article can be found at https://doi. org/10.1186/s12885-023-11790-6.

\*Correspondence:

Xiaoyan Lin

0591linxiaoyan@sina.com

<sup>1</sup>Department of Medical Oncology, Fujian Medical University Union Hospital, No.29, Xinquan Road, Gulou District, 350001 Fuzhou, Fujian province, China

<sup>2</sup>Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, 350014 Fuzhou, Fujian province, China

<sup>3</sup>Fujian Key Laboratory of Translational Cancer Medicine, Fujian Cancer Hospotial, No.91, Fuma Road, Jin'an District, 350014 Fuzhou, Fujian province, China

<sup>4</sup>Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Fujian Normal University Qishan Campus,

350117 College Town, Fuzhou, Fujian Province, PR China <sup>5</sup>Department of Breast Surgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 91, Fuma Road, Jin'an District, 350014 Fuzhou, Fujian province, China

<sup>6</sup>Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, 350014 Fuzhou, Fujian province, China The original article [1] has been corrected.

Published online: 25 March 2024

### References

 Huang W, Wang C, Shen Y, et al. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer. BMC Cancer. 2024;24:39. https://doi.org/10.1186/s12885-023-11790-6.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org//Licenses/by/4.0./. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.